Using CRISPR to Personalize Cancer Immunotherapy Treatment
In 2020, there were an estimated 18.1 million cases of cancer worldwide (excluding non-melanoma skin cancer). Breast, lung, and colorectal cancer were the most common and together contributed to 35.4% of these cases. In the same year, 9.5 million cancer-related deaths were reported. According to ...
Trainee Spotlight Series: OTS 2022 Poster Winners
Time: 5pm Amsterdam - 9 AM MST Date: January 26th, 2023 Topic / Speakers: Quantitative measurement of cytosolic and nuclear penetration of oligonucleotide therapeutics and investigation of sequence-penetration relationships Nefeli Batistatou, MSc Nefeli Batistatou, ...
2022 OTS Poster Award Winners
P004 Allien Balian Nucleic acid probes as biorecognition molecules for cancer detection P019 Chisato Terada BROTHERSTM platform: overcoming toxicity using a novel antisense architecture P030 Dhrubajyoti Datta PhD Evaluation of the Role of Epigenetic Modifications in siRNAs with 2′-Modified, N6-Alkyl Adenosine Nucleotides: Maintaining RNAi Potency ...
2022 OTS Travel Grant Recipients
Florian Peter Weissenböck, Institute of Biochemistry, University of Münster Jillian Belgrad, University of Massachusetts Chan Medical School Dyah Karjosukarso, PhD, Radboud University Medical Center Irene Vázquez-Domínguez, PhD, Radboud University Medical Center Christine Wuebben, PhD, University Hospital Bonn Irene González, Universitat de València Yvonne Jongejan, ...
Will N-of-1 Drugs Play a Role in the Future of Medicine?
Throughout the millennia, anyone who had anything beyond a simple illness could only do their best to ease the pain and petition whatever deities their culture believed in. Then, in the past few centuries, medicine and science have advanced to the point that many ...
Centyrins Effectively and Safely Deliver siRNAs to Multiple Muscle Tissues
In 2018, Susan Dillon and Karyn O'Neil knew they had created something special that could change the treatment of genetic diseases. Now, their company’s drug that uses their proprietary technology has been granted orphan drug status by the U.S Food and Drug Administration (FDA). ...
Reflections following the 20th annual meeting on oligonucleotide therapeutics
Footnote from title: modified slightly from “A brief history of oligonucleotide therapeutics” in the Timmerman Report, copyright 2022, and reprinted with permission. A Brief History of Oligonucleotide Therapeutics About 50 years ago, several scientists independently conceived of the idea of blocking gene expression with ...
2022 Annual Meeting Highlights
We truly enjoyed meeting in person again this year and hope those of you who were able to attend enjoyed it as well. We want to share interesting highlights from a few of the sessions. If you missed a talk or want to go ...
Delivery of Chemically Stabilized RNAi molecules to the Central Nervous System
Time: 11am - 12pm ESTDate: December 1, 2022 Description: Dr. Godinho will talk about the developments on delivery and PK/PD of novel oligonucleotides for CNS applications Speaker: Bruno M.D.C. Godinho Sr. Scientist Atalanta Therapeutics ...
An insider’s view into the preclinical development of an approved exon skipping drug
Time: 11am - 12pm EST Date: November 3, 2022 Description: Dr. Arechavala works on developing new drugs for neuromuscular disorders. As there are not many for these rare diseases, neuromuscular disorders have been at the forefront of the clinical development of RNA based ...
